/Renhe Pharmaceutical: Renhe Pharmaceutical Co., Ltd. Short Form Equity Change Report

NEWS

Renhe Pharmaceutical: Renhe Pharmaceutical Co., Ltd. Short Form Equity Change Report

Shenzhen Stock Exchange

2026/06/12

Renhe Pharmaceutical Co., Ltd.

Simplified Equity Change Report

Listed company name: Renhe Pharmaceutical Co., Ltd.

Stock listing location: Shenzhen Stock Exchange

Stock abbreviation: Renhe Pharmaceutical

Stock code: 000650

Information disclosure obligor: Yang Wenlong

Residence: *********, Zhangshu City, Jiangxi Province

Mailing address: No. 6, Gexuan Road, Zhangshu City, Yichun City, Jiangxi Province

Nature of change in equity: decrease

Signing date: June 2026

Statement of Information Disclosure Obligor

This report is prepared in accordance with the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Measures for the Administration of Acquisitions of Listed Companies", "Guidelines No. 15 on the Content and Format of Information Disclosure by Companies Offering Securities to the Public - Report on Changes in Equity" and relevant laws, regulations and normative documents.
The information disclosure obligor has obtained the necessary authorization and approval to sign this report, and its performance does not violate or conflict with any provision in the information disclosure obligor's charter or internal rules.
In accordance with the "Securities Law of the People's Republic of China", "Measures for the Administration of Acquisitions of Listed Companies" and other regulations, this report has fully disclosed the changes in shares held by the information disclosure obligor in Renhe Pharmaceutical Co., Ltd.
As of the signing date of this report, except for the information disclosed in this report, the information disclosure obligor has not increased or decreased its equity shares in Renhe Pharmaceutical Co., Ltd. through any other means.
This change in equity is based on the information stated in this report. Except for the information disclosure obligor, no unit or individual has been entrusted or authorized to provide information not included in this report or to provide any explanation or explanation for this report.
The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and assumes individual and joint legal liability for the authenticity, accuracy and completeness of its contents.

Section 1 Introduction to the Information Disclosure Obligor

1. Basic information of information disclosure obligors

Name Yang Wenlong

Previous names: None

Gender male

Nationality China

ID number 3622031962********

Residence: Zhangshu City, Jiangxi Province********

Mailing address: No. 6, Gexuan Road, Zhangshu City, Yichun City, Jiangxi Province

Communication method 0791-83896755

Whether you have obtained the right of residence in other countries or regions? No

The information disclosure obligor’s equity interests in other domestic or overseas listed companies reach or exceed 5% of the company’s issued shares; the situation of financial institutions holding more than 5% of the shares

As of the signing date of this report, except for Renhe Pharmaceutical, the shares held by the information disclosure obligor in other domestic and overseas listed companies reached or exceeded 5% of the company's issued shares as follows:

Stock abbreviation Stock code Main business Shareholding ratio

Dingdang Health 09886.HK Quick medicine business, online consultation, chronic disease and health management business owns 50.04% equity

As of the signing date of this report, the information disclosure obligor does not own more than 5% of the equity in other financial institutions such as banks, trust companies, securities companies, insurance companies, etc.

Section 2 Purpose of Equity Change

1. Purpose of this equity change

This equity change is to promote the company's steady development and adjust the company's actual control within the family. After this equity change, the company's controlling shareholder is still Renhe (Group) Development Co., Ltd., and the actual controller has been changed from Yang Wenlong to Yang Xiao.

2. Share change plan in the next 18 months

As of the signing date of this report, in addition to the equity changes disclosed in this report, the information disclosure obligor does not rule out increasing the shares of listed companies in the next 18 months based on the overall situation of the securities market, the operating development of listed companies and other factors.

If changes in equity occur in the future, the information disclosure obligors will perform corresponding procedures and disclosure obligations in accordance with the requirements of relevant laws and regulations.

Section 3 Equity Change Methods

1. Information disclosure obligors’ equity holdings in listed companies before and after this equity change

As of the signing date of this report, Renhe Group holds 325,299,386 shares of the listed company, accounting for 23.24% of the total shares of the listed company, and is the controlling shareholder of the listed company.

Before this equity change, Mr. Yang Wenlong directly held 73.1137% of the shares of the listed company's controlling shareholder.

On June 10, 2026, the company's actual controller Mr. Yang Wenlong and his son Yang Xiao signed an agreement. The company's actual controller Mr. Yang Wenlong planned to transfer 73.1137% of the equity he held in Renhe Group to his son Mr. Yang Xiao. This agreement was established and effective from the date of signature by both parties.

After this equity change, Mr. Yang Wenlong no longer holds the equity of Renhe Group. Mr. Yang Xiao holds 73.1137% of the equity of Renhe Group. The company’s controlling shareholder, Renhe Group, holds 23.24% of the company’s shares. The controlling shareholder of the company is still Renhe Group, and the actual controller of the listed company has been changed from Yang Wenlong to Yang Xiao.

This equity change is a change in the equity structure of the company's controlling shareholder, an adjustment to the equity structure within the family of the actual controller, and does not involve changes in the company's shares held by Renhe Group. Before and after this equity change, the equity control relationship of the listed company is as follows:

Before change:

Yang Wenlong

73.11%

Yang Xiao Renhe Group

6.53% 23.24%

Renhe Pharmaceutical

After the change:

73.11%

Yang Xiao Renhe Group

6.53% 23.24%

Renhe Pharmaceutical

2. Main contents of the equity transfer agreement for this equity change

On June 10, 2026, the company's actual controller Yang Wenlong and his son Yang Xiao signed an agreement. Yang Wenlong transferred his subscribed capital contribution of RMB 137.5853 million to Renhe Group, accounting for 73.1137% of the registered capital of the target company, to Yang Xiao. Both parties confirmed that Yang Xiao does not need to pay any monetary equity transfer price to Yang Wenlong for this transfer of the target equity, and the agreement will take effect from the date of signing.

On June 10, 2026, the shareholders' meeting of Renhe Group reviewed and approved the above-mentioned equity transfer.

3. Restrictions on share rights

This equity change is the transfer of the equity of Renhe Group, the controlling shareholder of the listed company, by the information disclosure obligor. As of the signing date of this report, these equity interests have not been pledged, frozen or otherwise have their rights restricted.

In addition, as of the signing date of this report, the 325,299,386 shares of the listed company held by Renhe Group have not been pledged, frozen or otherwise restricted.

4. Other matters related to this equity change

After this equity change, Renhe Group still needs to complete the industrial and commercial change registration procedures.

Section 4. Purchase and sale of shares of listed companies within the previous six months. In the six months prior to the date of the change in equity, the information disclosure obligor and his immediate family members did not buy or sell shares of listed companies through the stock exchange.

Section 5 Other Major Matters

The information disclosure obligor has truthfully disclosed the relevant information of this equity change in accordance with relevant regulations. There is no other information that must be disclosed but has not been disclosed to avoid misunderstandings about the content of the equity change report, and there is no other information that the China Securities Regulatory Commission or the stock exchange requires disclosure in accordance with the law but has not been disclosed.

Section 6 Documents for Inspection

1. File directory for reference

(1) Identity document of the person with information disclosure obligation;

(2) Agreements involved in this equity change;

(3) Resolution of the shareholders’ meeting of Renhe Group;

(4) This report signed by the information disclosure obligor;

(5) Other materials required by the China Securities Regulatory Commission and Shenzhen Stock Exchange.

2. Location of documents for reference

The above documents shall be kept at the address of the listed company for inspection.

Statement of Information Disclosure Obligor

The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and assumes individual and joint legal liability for its authenticity, accuracy and completeness.

Information disclosure obligor:

Yang Wenlong

Attachment on June 11, 2026: Simplified Equity Change Report

Simplified Equity Change Report

Basic situation

Renhe Pharmaceutical Co., Ltd. has

Name of the listed company Location of the listed company No. 6, Gexuan Road, Zhangshu City, Yichun City, Jiangxi Province

Ltd.

Stock abbreviation Renhe Pharmaceutical Stock code 000650

The person with the information disclosure obligation lives in

Name of person with information disclosure obligation: Yang Wenlong Zhangshu City, Jiangxi Province

increase ☐

The number of shares owned decreases √

Are there any persons acting in concert? Yes ☐ None √Change No change, but shareholders

changes ☐

Is the person with the obligation to disclose information? Is the person with the obligation to disclose information?

It is the largest share of the listed company Yes ☐ No √ No It is the actual controller of the listed company Yes √ No ☐dong

Through centralized trading on the stock exchange ☐ Transfer by agreement ☐ Mode of change in equity (multiple choices available: Administrative transfer or change of state-owned shares ☐ Transfer by indirect means √) Obtain new shares issued by a listed company □ Execute court ruling ☐ Inheritance ☐ Gift ☐ Others ☐

Type of shareholding: RMB ordinary shares (A shares)

Information disclosure obligor discloses the number of shares held: 325,299,386 shares (indirect)

Number of shares previously owned Shareholding ratio: 23.24%

Before this equity change, the information disclosure obligor held 73.1137% of the shares of Renhe Group Co., Ltd., the largest shareholder of the listed company, and thus indirectly controlled 325,299,386 shares of the listed company, accounting for 23.24% of the total shares of the listed company.

Type of change: RMB ordinary shares (A shares)

Changes in the number of equity interests that occurred this time: reduction of 325,299,386 shares indirectly controlled

The number and proportion of changes in shares: reduced indirect control by 23.24%

Moving ratio After this equity change, the information disclosure obligor transferred 73.1137% of the equity of Renhe Group and no longer indirectly

Controls 325,299,386 shares of listed companies.

Ownership in a listed company Time: Date of signature of the agreement

The time of change of Yi’s shares: Mr. Yang Wenlong, the actual controller of the company, plans to transfer 73.1137% of the equity he holds in the company’s controlling shareholder Renhe Group and Mode to his son, Mr. Yang Xiao.

Have funds been fully disclosed?

Yes ☐ No √ (not applicable) Source

Is the person with the information disclosure obligation

Planned to continue within the next 12 months Yes ☐ No √

Continue to increase holdings

Top 6 persons with information disclosure obligations

Whether to buy in the secondary market in month? Yes ☐ No √

Sell the shares of the listed company

If it involves the reduction of shares held by the controlling shareholder or actual controller of a listed company, the information disclosure obligor shall also explain the following:

Controlling shareholder or actual control Yes ☐ No √

Whether there is any problem of infringing on the rights and interests of listed companies and shareholders when reducing their holdings

Whether the controlling shareholder or actual controller has unpaid liabilities to the company when it reduces its holdings,

Yes ☐ No √The guarantee provided by the company for its liabilities has not been released, or other circumstances have harmed the interests of the company. Whether approval is required for this equity change and the progress of approval Yes ☐ No √Situation

Has it been approved? Yes ☐ No √ (not applicable) (This page has no text, it is the signature page of the attachment to the "Renhe Pharmaceutical Co., Ltd. Simplified Equity Change Report")

Information disclosure obligor:

Yang Wenlong

June 11, 2026